-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glioblastoma is the most common primary brain tumor.
A total of 47 pretreated patients (2-65 mg) from 8 cohorts were included in the study.
At 45 mg/day, the steady-state concentration of GDC-0084 exceeds the pre-clinical target concentration, producing anti-tumor activity in a xenograft model.
In summary, the results of this study indicate that GDC-0084 exhibits typical PI3K/mTOR inhibitor-related toxicity.
Original source:
Patrick Y Wen, et al.
ncbi.
nlm.
nih.
gov/31937616/" target="_blank" rel="noopener">First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K / mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma in this message